Media Outlets Highlight Research by Dr. Çagla Tükel and School of Medicine Team That Shows First-of-Its-Kind Molecule Is a Promising Strategy in Fighting Biofilms

Çagla Tükel, PhD, Associate Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University, was the senior author on a new study published online in the journal Nature Communications that showed a first-of-its-kind therapeutic molecule, a type of monoclonal antibody, shows promise as an immunotherapeutic strategy to break apart communities of harmful bacteria known as biofilms and open the way for antibiotics. These biofilms are notorious for forming on implanted medical devices and on tissues in the body, where they give rise to chronic and sometimes life-threatening infections in patients. Multiple media outlets, including Bioengineer.org, Scienmag, News-Medical.net and ScienceDaily, reported on the findings.